More recently, evidence has accumulated that the EML4-ALK fusion gene defines a novel subclass of lung adenocarcinomas with distinct clinicopathological features[7-9], so that it has emerged as a target for therapy. This evidence concerns the gene EML4 and lung adenocarcinoma.